Objective: To investigate the degree of pain reduction in patients with complex regional pain syndrome type 1 (CRPS 1) that can be defined as "successful."
Complex regional pain syndrome type 1 (CRPS 1), formerly known as reflex sympathetic dystrophy, is a post-traumatic syndrome with pain that is not related to the territory of a single nerve and is disproportionate to the inciting event. 1 No specific test is currently available to diagnose this syndrome, and the diagnosis of CRPS 1 has to be based solely on subjective measurements of clinical symptoms. In clinical studies on CRPS 1, pain assessment is a crucial measurement. The visual analog scale (VAS) is normally used to assess the pain intensity. A treatment is defined as successful when the pain after intervention is significantly reduced compared with baseline or control group measures. [2] [3] [4] [5] [6] [7] Farrar et al 8 showed that a percentage pain intensity difference of more than 33% is an accurate cut-off point in reflecting clinically important improvement for patients treating for breakthrough cancer pain. Furthermore, in rheumatoid arthritis a 36% overall improvement should be considered as clinically important. 9 In CRPS 1 studies a pain reduction of 30% to 50% has been claimed to demonstrate that a treatment is successful. [10] [11] [12] [13] To our knowledge, however, it is still not clear what degree of pain reduction is clinically relevant for CRPS 1 patients. We undertook the present study to investigate the clinically relevant pain reduction in patients with CRPS 1.
MATERIALS AND METHODS

Subjects
The data for this study consisted of the pain intensity assessments in 52 patients with CRPS 1 participating in a previously reported randomized trial on the effectiveness of spinal cord stimulation.
14 Furthermore, 9 patients who were treated with spinal cord stimulation but who did not participate in the trial were included in this study. The diagnostic criteria for CRPS 1, developed by the International Association for the Study of Pain, 15 were used for all patients. In addition, patients had to show impaired function and extension of symptoms outside the area of trauma.
Procedure
All patients were asked to rate their pain on a VAS (0-10 cm) 3 times a day during a period of 4 days. The VAS was anchored by 2 extremes of pain: "no pain" on the left and "the worst possible pain" on the right end. In addition, all patients rated the Global Perceived Effect (GPE) on a seven-point scale (1, worst ever; 2, much worse; 3, a little worse; 4, not changed; 5, a little improved; 6, much improved; and 7, best ever). The GPE was translated from English into Dutch.
14 These VAS and GPE measurements were made before treatment and at 6-month, 1-year, and 2-year follow-up.
Statistics
Global Perceived Effect scores of 6 and 7 were classified as "successful" and GPE scores of 1-5 were defined as "unsuccessful." For both "successful" and "unsuccessful" the mean absolute and relative pain reduction was calculated for the pain intensity (VAS) for each consecutive follow-up period. Parametric data were analyzed using t tests.
We used 2 × 2 tables to calculate the sensitivity, specificity, and accuracy values for different cut-off points in absolute and relative pain intensity reduction. 8 These pain intensity reductions were compared with the GPE classifications (ie, "successful" and "unsuccessful"). Table 1 shows the definition of sensitivity, specificity, and accuracy as used in the present study. The best cutoff point was selected by two authors (T.F. and W.E.J.W.) and was defined as one with the highest overall accuracy coupled with the best balance of sensitivity and specificity. When similar levels of accuracy occurred, the cut-off point with a reasonable value for both sensitivity and specificity was chosen.
RESULTS
There were no significant differences between the groups with regard to mean pretreatment VAS scores and mean age (t test; P > 0.1). Therefore, both groups were combined into one study-population, which consisted of 19 male and 42 female patients. The mean age was 43 years (43.1 ± 10.6 [standard deviation], and the mean pretreatment VAS score was 7.1 (7.1 ± 1.5 [standard deviation]).
The pain scores for each consecutive follow-up period are listed using the classification "successful" and "unsuccessful" ( Table 2 ). The overall pain reduction according to all levels of the GPE is listed in Table 3 . For both "successful" and "unsuccessful" patients the absolute pain was reduced significantly in all folow-up periods (P < 0.05). "Successful" is defined as "much improved" and "best ever" according to the Global Perceived Effect scale; "unsuccessful" is defined as "a little improved," "not changed," "a little worse," "much worse," and "worst ever."
Of the 2-year follow-up data, the results for 5 patients were missing. The absolute pain reduction of both "successful" and "unsuccessful" patients was decreased significantly during the follow-up assessments (P < 0.05). A relative pain reduction between 58% (SD, 23.4) and 71% (SD, 16.3) and an absolute pain reduction between 4.2 (SD, 2.0) and 4.8 (SD, 1.6) was scored as "successful" by the patients, whereas a relative pain reduction of 13% (SD, 35.2) or less was noted as "unsuccessful." An absolute pain reduction of 1.1 (SD, 2.4) was defined as "unsuccessful."
The frequency distribution of VAS scores associated with "successful" and "unsuccessful" is shown in Figure  1 . The ranges of percent improvement in VAS are: <0 (increase in pain compared with baseline), 0 to <20, 20 to <40, 40 to <60, 60 to <80, and 80 to 100. At 6-month follow-up all patients reported a pain reduction of 40% or more. At the 1-year and 2-year follow-ups, 90.5% and 72.2%, respectively, of the patients reported a pain reduction of at least 40%. Table 4 shows the calculated sensitivity, specificity, and accuracy values at various cut-off points. A cut-off point of Ն50% relative pain reduction showed the highest accuracy with the best balance of sensitivity and specificity. In the 6-month follow-up this cut-off point resulted in a sensitivity of 93.8% and a specificity of 80.0% with an accuracy of 83.6%. In other words, "successful" patients on the GPE are associated with a 93.8% likelihood reporting a relative pain intensity reduction of Ն50%, whereas "unsuccessful" patients have an 80.0% likelihood reporting <50% relative pain reduction. The calculation for the absolute pain reduction showed that an absolute pain reduction of 3 cm or more as measured on the VAS is an accurate pain reduction.
DISCUSSION
In the CRPS 1 literature most clinical studies use pain ratings as the primary outcome measure. In most of these Values are given as mean ± standard deviation. None of the patients reported "best ever" on the Global Perceived Effect scale. studies a significant pain reduction after treatment is defined as successful. [2] [3] [4] [5] [6] [7] Some authors define a pain reduction of 30% to 50% as successful. [10] [11] [12] [13] A clinically relevant pain reduction in patients with CRPS 1, however, is still not defined.
In the present study we have shown that CRPS 1 patients define a relative pain reduction of 58% or more as "successful." In both "successful" and "unsuccessful" patients the pain was reduced significantly. Furthermore, a relative pain reduction of 50% or more as a cut-off point proved to be the most accurate point with the best sensitivity and specificity. For the absolute pain reduction, the 3-cm mark on VAS could be defined as an accurate cut-off point.
Our study compared the GPE with the VAS. The GPE was used as the "gold standard" in this comparison, a use that may be questionable. The VAS measures the patient's pain intensity. Pain assessment using a VAS score before and after a given treatment will show only a decrease or increase of the pain intensity. It gives less information about the degree of success of a treatment, as defined by the patients. Therefore, using a VAS to term a treatment successful or not would be a physician-based rather than a patient-based judgment. The GPE, in contrast, has the advantage of assessing the degree of treatment success as defined by the patient, making any statement, therefore, patient based.
A relative pain reduction of 30% to 50% has often been used as the definition of a positive outcome in analgesic studies. [10] [11] [12] [13] In defining cut-off points several authors have used different outcomes-an additional dose of rescue medication, 8 experts' opinion, 9, 16 or the seven-point Likert scale, 17, 18 for instance-as the gold standard by which to evaluate the effectiveness of the study intervention. These standards have potential limitations. In using the additional dose of rescue medication as a standard, for example, one must consider the factors other than pain that may play a role in the patient's decision to take a rescue doses. Regarding experts' opinion, the inaccuracy of observers in assessing patients' pain or psychosocial state has been described by several studies [19] [20] [21] [22] [23] ; comparison of the experts' opinion with patients' pain may bias the results. In the use of the Likert scale, the comparison of that scale with a quality-of-life measurement or pain intensity assessment is a comparison of two subjective scales, and the results may be biased by the patient's sense of what the interviewer wants to hear or what the patient thinks the answer ought to be. The patient (using the Likert scale) may report satisfaction to please the doctor, because they were seen more quickly, or simply because the patient's mood has improved. In contrast, in using the VAS in a clinical setting, the patients may report less pain after treatment because reporting otherwise would be too cognitively dissonant to be acceptable.
We compared two subjective measurements to identify a meaningful pain reduction in patients with CRPS 1. The aforementioned limitations must therefore be considered in the present study. Further, for our study the GPE was translated into Dutch, which may affect our results. We used the term "best ever" instead of "very much improved"; the classification "best ever" may be interpreted as the maximal improvement that can be achieved after treatment-which could explain why none of our patients reported "best ever" at the follow-up periods.
Despite these shortcomings we hypothesize that, in patients with CRPS 1, a significant pain reduction after treatment, as measured by the VAS, does not necessarily imply that the patient defines the treatment as successful. Furthermore, a relative pain reduction of 50% or more and an absolute pain reduction of at least 3 cm on the VAS are accurate in predicting a successful pain reduction after a given treatment.
To support these hypotheses prospective studies are indispensable. Furthermore, we emphasize that, in future clinical studies on CRPS 1, the VAS and a GPE scale should be used side by side, to measure patients' pain and the degree of improvement according the patients.
